#1 Clinical Trials Search in Europe

Bicalutamide

Bicalutamide, also known by its brand name Casodex, is a drug that has been the subject of various clinical trials for its potential in treating different types of cancer. These trials primarily focus on prostate cancer and certain breast cancers, exploring the drug’s effectiveness, safety, and impact on patients’ quality of life. The studies range from bioequivalence tests to combination therapies with other drugs, providing valuable insights into the role of bicalutamide in cancer treatment.

Table of Contents

What is Bicalutamide?

Bicalutamide is a medication primarily used in the treatment of prostate cancer. It’s also known by its brand name Casodex[1]. Bicalutamide belongs to a class of drugs called nonsteroidal antiandrogens, which means it works by blocking the effects of male hormones (androgens) in the body[3].

How Does Bicalutamide Work?

Bicalutamide works by blocking testosterone at the receptor level. This means it prevents testosterone from attaching to and activating cells in the prostate gland. By doing this, it helps to slow down or stop the growth of prostate cancer cells, which often rely on testosterone to grow[3].

Unlike some other prostate cancer treatments, bicalutamide doesn’t reduce the overall levels of testosterone in the body. This unique mechanism of action can potentially lead to fewer side effects compared to treatments that lower testosterone throughout the body[3].

Conditions Treated with Bicalutamide

Bicalutamide is primarily used to treat:

  • Prostate Cancer: It’s most commonly used for advanced prostate cancer, particularly in cases where the cancer has progressed despite initial hormone therapy[1][3].
  • Triple-Negative Breast Cancer: Some research is exploring the use of bicalutamide in certain types of breast cancer, specifically in patients with androgen receptor-positive triple-negative breast cancer[4].

Dosage and Administration

Bicalutamide is typically taken orally (by mouth) in tablet form. The dosage can vary depending on the specific condition being treated and individual patient factors:

  • For prostate cancer, common dosages range from 50 mg to 150 mg daily[1][3].
  • In some research studies, dosages up to 200 mg daily have been used[5].
  • For breast cancer research, a dose of 150 mg daily has been studied[4].

It’s important to note that bicalutamide should only be taken as prescribed by a healthcare professional, who will determine the appropriate dosage based on your specific condition and needs.

Effectiveness of Bicalutamide

Research has shown that bicalutamide can be effective in treating prostate cancer. In clinical trials, it has demonstrated the ability to slow disease progression and improve survival rates in some patients[1].

One study compared bicalutamide to another drug called enzalutamide in patients with prostate cancer. The study looked at how long it took for the cancer to progress (called progression-free survival). While the exact results weren’t provided, the study suggests that both drugs were effective in delaying cancer progression[1].

In breast cancer research, bicalutamide has shown promise in early studies for treating certain types of triple-negative breast cancer. However, more research is needed to fully understand its effectiveness in this area[4].

Side Effects and Safety

Like all medications, bicalutamide can cause side effects. Common side effects may include:

  • Hot flashes
  • Breast tenderness or enlargement
  • Fatigue
  • Nausea
  • Skin rash

In clinical trials, researchers closely monitored patients for adverse events (side effects). They paid particular attention to serious side effects and specific issues like mucositis (inflammation of the lining of the digestive system), rash, and fatigue[10].

It’s important to discuss potential side effects with your healthcare provider. They can provide more information and help manage any side effects that may occur.

Impact on Quality of Life

One of the potential benefits of bicalutamide is its impact on quality of life. Because it doesn’t lower overall testosterone levels in the body, it may have fewer side effects on things like bone density, muscle strength, and sexual function compared to some other prostate cancer treatments[3].

Research has been conducted to specifically look at how bicalutamide affects quality of life in prostate cancer patients. These studies use questionnaires to assess various aspects of well-being, including physical, emotional, and social functioning[1][9].

Ongoing Research and Future Directions

Research on bicalutamide is ongoing, with scientists exploring its use in different conditions and in combination with other treatments. Some areas of current research include:

  • Combination therapy with other drugs for prostate cancer, such as RAD001 (also known as everolimus)[10].
  • Use in triple-negative breast cancer, particularly in combination with other targeted therapies like abemaciclib[6].
  • Comparing different hormone therapy approaches in prostate cancer patients undergoing radiation therapy[9].

These ongoing studies aim to further understand how bicalutamide can be used most effectively to treat various types of cancer and improve patient outcomes.

Aspect Details
Primary Uses Prostate cancer, Androgen Receptor-positive Triple-Negative Breast Cancer
Mechanism of Action Androgen receptor antagonist, blocks testosterone at receptor level
Common Dosages 50 mg, 150 mg, 200 mg daily (varies by study and condition)
Combination Therapies With LHRH agonists, abemaciclib, RAD001 (everolimus)
Efficacy Measures PSA levels, objective response rate, progression-free survival, overall survival, quality of life
Safety Monitoring Liver function, bone mineral density, muscle strength, breast tenderness/gynecomastia
Quality of Life Impact Studied in comparison to total androgen blockade in some trials
Bioequivalence Studies Compared with brand-name Casodex under fed and fasting conditions

FAQ

  • What is bicalutamide and how does it work? Bicalutamide is an oral, non-steroidal, androgen receptor (AR) antagonist. It works by blocking testosterone at the receptor level, allowing androgen deprivation in certain tissues without reducing circulating levels of testosterone. This mechanism makes it useful in treating hormone-sensitive cancers like prostate cancer.
  • In which types of cancer is bicalutamide being studied? Bicalutamide is primarily studied in prostate cancer, but recent trials have also explored its potential in treating certain types of breast cancer, specifically androgen receptor (AR)-positive metastatic triple-negative breast cancer (mTNBC).
  • What are some common dosages of bicalutamide used in clinical trials? Clinical trials have explored various dosages of bicalutamide. Common dosages include 50 mg daily, 150 mg daily, and in some cases, 200 mg daily. The dosage often depends on the specific condition being treated and whether bicalutamide is used alone or in combination with other drugs.
  • Are there any notable side effects of bicalutamide? While side effects can vary, some trials have monitored for specific adverse events such as changes in liver function, changes in bone mineral density, and effects on muscle strength. Some patients may experience breast tenderness or gynecomastia, for which additional medications like tamoxifen may be prescribed.
  • How is the effectiveness of bicalutamide measured in clinical trials? The effectiveness of bicalutamide is often measured through various outcomes, including PSA (Prostate-Specific Antigen) levels, objective response rate, progression-free survival, overall survival, and quality of life measures. In some trials, researchers also look at bone mineral density, muscle strength, and other physical parameters.

Ongoing Clinical Trials on Bicalutamide

  • Comparison of Short vs Long-term Hormone Therapy with Goserelin, Leuprorelin, or Triptorelin Combined with Radiation for Prostate Cancer Patients After Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Selumetinib, Bicalutamide, and Olaparib in Patients with Metastatic Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Bicalutamide and Drug Combination for Patients with Unfavorable Intermediate/High-Risk Prostate Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Bicalutamide and Abemaciclib for Patients with Advanced Androgen Receptor Positive Triple-Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of Dutasteride with Goserelin Acetate and Bicalutamide in Patients with Recurrent or Metastatic Salivary Duct Carcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Prostate Cancer: Comparing Stereotactic Body Radiation Therapy Alone or with Triptorelin and Bicalutamide for Patients with Acinar Cell Prostatic Carcinoma

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study Comparing Rezvilutamide and Bicalutamide with Hormone Therapy for Patients with Advanced Prostate Cancer

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Poland

  • Study on Enzalutamide and Drug Combination for High-Risk Localized Prostate Cancer Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Ireland Spain

  • Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy Poland +3

Glossary

  • Androgen Receptor (AR): A type of nuclear receptor that is activated by binding androgens, such as testosterone. It plays a crucial role in the development and function of male reproductive organs and is a target for certain cancer treatments.
  • Bioequivalence: The property wherein two drugs with identical active ingredients or two different dosage forms of the same drug possess similar bioavailability and produce the same effect at the site of physiological activity.
  • Castration-Resistant Prostate Cancer (CRPC): A type of prostate cancer that continues to progress despite androgen deprivation therapy (ADT) that reduces testosterone levels in the body.
  • Clinical Benefit Rate (CBR): The percentage of patients who achieve complete response, partial response, or stable disease for a specified period (often 24 weeks or more) in a clinical trial.
  • Gleason Score: A grading system used to determine the aggressiveness of prostate cancer, based on how the cancer cells look under a microscope.
  • Gynecomastia: The enlargement of breast tissue in males, which can be a side effect of certain hormonal treatments.
  • Luteinizing Hormone-Releasing Hormone (LHRH) agonist: A type of drug that reduces testosterone production in the body, often used in the treatment of prostate cancer.
  • Metastatic Triple-Negative Breast Cancer (mTNBC): A type of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 protein, and has spread beyond the breast to other parts of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer or other prostate conditions.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess changes in tumor size during cancer treatment.

References

  1. https://clinicaltrials.gov/study/NCT01664923
  2. https://clinicaltrials.gov/study/NCT01044706
  3. https://clinicaltrials.gov/study/NCT00551044
  4. https://clinicaltrials.gov/study/NCT02348281
  5. https://clinicaltrials.gov/study/NCT00846976
  6. https://clinicaltrials.eu/trial/study-of-bicalutamide-and-abemaciclib-for-patients-with-advanced-androgen-receptor-positive-triple-negative-breast-cancer/
  7. https://clinicaltrials.gov/study/NCT00972855
  8. https://clinicaltrials.gov/study/NCT00973050
  9. https://clinicaltrials.gov/study/NCT02382094
  10. https://clinicaltrials.gov/study/NCT00630344